<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">World J Orthop</journal-id><journal-id journal-id-type="publisher-id">WJO</journal-id><journal-title-group><journal-title>World Journal of Orthopedics</journal-title></journal-title-group><issn pub-type="epub">2218-5836</issn><publisher><publisher-name>Baishideng Publishing Group Inc</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">28660137</article-id><article-id pub-id-type="pmc">5478488</article-id><article-id pub-id-type="other">jWJO.v8.i6.pg461</article-id><article-id pub-id-type="doi">10.5312/wjo.v8.i6.461</article-id><article-categories><subj-group subj-group-type="heading"><subject>Minireviews</subject></subj-group></article-categories><title-group><article-title>Role of fetuin A in the diagnosis and treatment of joint arthritis</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Pappa</surname><given-names>Eleni</given-names></name></contrib><contrib contrib-type="author"><name><surname>Perrea</surname><given-names>Despina S</given-names></name></contrib><contrib contrib-type="author"><name><surname>Pneumaticos</surname><given-names>Spiridon</given-names></name></contrib><contrib contrib-type="author"><name><surname>Nikolaou</surname><given-names>Vasileios S</given-names></name></contrib><aff>Eleni Pappa, Despina S Perrea, Laboratory of Experimental Surgery &#x0201c;N.S. Christeas&#x0201d;, National and Kapodistrian University of Athens, School of Medicine, 11527 Athens, Greece</aff><aff>Spiridon Pneumaticos, 3<sup>rd</sup> Department of Orthopaedics, KAT Hospital, National and Kapodistrian University of Athens, School of Medicine, 11527 Athens, Greece</aff><aff>Vasileios S Nikolaou, 2<sup>nd</sup> Department of Orthopaedics, Agia Olga Hospital, National and Kapodistrian University of Athens, School of Medicine, 11527 Athens, Greece</aff></contrib-group><author-notes><fn><p>Author contributions: Pappa E wrote the manuscript; Perrea DS and Pneumaticos S contributed to the writing of the manuscript; Nikolaou VS contributed to the writing of the manuscript and did the final proof editing.</p><p>Correspondence to: Vasileios S Nikolaou, MD, PhD, MSc, Orthopaedic Surgeon, Assistant Professor of Orthopaedics, 2<sup>nd</sup> Department of Orthopaedics, Agia Olga Hospital, National and Kapodistrian University of Athens, School of Medicine, 21 Dimitriou Ralli Str, 11527 Athens, Greece. <email>bniko@med.uoa.gr</email></p><p>Telephone: +30-693-2543400 Fax: +30-210-8020671</p></fn></author-notes><pub-date pub-type="collection"><day>18</day><month>6</month><year>2017</year></pub-date><pub-date pub-type="epub"><day>18</day><month>6</month><year>2017</year></pub-date><volume>8</volume><issue>6</issue><fpage>461</fpage><lpage>464</lpage><history><date date-type="received"><day>20</day><month>1</month><year>2017</year></date><date date-type="rev-recd"><day>23</day><month>4</month><year>2017</year></date><date date-type="accepted"><day>3</day><month>5</month><year>2017</year></date></history><permissions><copyright-statement>&#x000a9;The Author(s) 2017. Published by Baishideng Publishing Group Inc. All rights reserved.</copyright-statement><copyright-year>2017</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/"><license-p><!--CREATIVE COMMONS-->Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/">http://creativecommons.org/licenses/by-nc/4.0/</ext-link></license-p></license></permissions><abstract><p>Osteoarthritis is a slowly progressive disease which includes the intervention of several cytokines, macrophage metalleinoproteinases reaction, leading to the degradation of the local cartilage but also having an impact on the serum acute phase proteins (APPs). Subsequently, biomarkers seem to be essential to estimate its progression and the need for any surgical intervention such as total arthroplasty, but also can be used as therapeutic agents. Recently, among APPs, fetuin A drew attention regarding its possible anti-inflammatory role in animal models but also as a therapeutic agent in the inflammatory joint disease in clinical trials. In contrast with other APPs such as C-reactive protein, fetuin A appears to be lower in the serum of patients with degenerative joint disease in comparison with the healthy ones, and also acts as an antagonist of the anti-proliferative potential of transforming growth factor-&#x003b2; (TGF-&#x003b2;) cytokines. Because of its lower serum levels in arthritis, an unregulated binding of TGF-&#x003b2; and bone morphogenetic proteins takes place leading to further arthritic lesions. The purpose of the present review is to assess the current evidence regarding the multipotent role of the alpha-2-HS-glycoprotein or as also known Fetuin-a in animal models but also as a biomarker of the degenerative joint arthritis in clinical trials.</p></abstract><kwd-group><kwd>Fetuin A</kwd><kwd>Arthritis</kwd><kwd>Alpha-2-HS-glycoprotein</kwd><kwd>Bone morphogenetic protein</kwd><kwd>Inflammation</kwd><kwd>Glycoprotein</kwd><kwd>Treatment</kwd></kwd-group></article-meta></front><body><p><bold>Core tip:</bold> Fetuin A, an acute phase glycoprotein, recently drew scientific attention regarding its anti-inflammatory role. In the case of arthritis, clinical studies have shown its therapeutic potential as well as its anti-inflammatory role as it has been indicated by animal models. In this manuscript, we intend to review the current evidence concerning its anti-inflammatory and therapeutic role in degenerative joint disease.</p><sec><title>INTRODUCTION</title><p>Osteoarthritis, which is also known as degenerative arthritis, is a deteriorating musculoskeletal condition that includes the decrease in the articular cartilage but also leads to a progressive subchondral erosion of the bone[<xref rid="B1" ref-type="bibr">1</xref>]. It is assumed that the joint arthritis consists of an inflammatory response which is introduced by several cytokines which are produced by the local reaction of macrophages, such as interleukin (IL)-1a, IL-8, IL-10 and matrix metalleinoproteinases (MMPs). These agents are measurable in the serum but also in the joint synovial fluid and all lead to cartilage breakdown[<xref rid="B2" ref-type="bibr">2</xref>]. Additional to the imbalance of the cytokines driven inflammatory process, the collagen of type 1 is transformed to collagen of type 2, while at the same time a decrease in the joint chondrocytes also takes place. It is widely accepted that the activity of IL-1 has a leading role in the arthritis inflammatory process leading to the production of MMPs which further leads to cartilage degradation. Acute phase proteins (APPs), such as C-reactive protein, are also elevated in patients with severe osteoarthritis[<xref rid="B2" ref-type="bibr">2</xref>,<xref rid="B3" ref-type="bibr">3</xref>].</p><p>Regarding APPs, fetuin A has recently draw attention regarding its possible anti-inflammatory role[<xref rid="B4" ref-type="bibr">4</xref>]. The complete structure of the complex oligosaccharides of fetuin A has been established[<xref rid="B5" ref-type="bibr">5</xref>]. Thanks to ion exchange chromatography following pronase digestion, identical molar ratios of sialic acid, mannose and N-acetylglycosamine of 3:3:3:5 was revealed (Figure <xref ref-type="fig" rid="F1">1</xref>).</p><fig id="F1" position="float"><label>Figure 1</label><caption><p>Structure of fetuin A.</p></caption><graphic xlink:href="WJO-8-461-g001"/></fig><p>Fetuin A is also known as alpha-2-HS-glycoprotein (AHSG) for the human homologue and was first declared as a fetus major plasma protein. During the fetus growth, it is expressed in the liver, kidney, gastrointestinal tract, skin and brain[<xref rid="B6" ref-type="bibr">6</xref>]. Concerning the adults, among APPs, fetuin A is produced by the liver and has recently drawn attention regarding its possible anti- inflammatory role in injury or infection, classifying it as a negative APP due to a regulation of pre-inflammatory cytokines such as tumor necrosis factor (TNF), IL-1, IL-6 and interferon (IFN)-&#x003b3;, but also as a positive APP thanks to the mediation of HMGB1[<xref rid="B7" ref-type="bibr">7</xref>].</p><p>The aim of this mini review is to investigate the possible role of fetuin A in the inflammatory response, in processes such as the joint osteoarthritis.</p></sec><sec><title>ETIOPATHOLOGY OF ARTHRITIS</title><p>The joint homeostasis seems to take place due to a balance between catabolic factors of the adult joint cartilage (IL-1 and TNF) as well as the anabolic ones [insulin like growth factor (IGF), bone morphogenetic protein (BMP) morphogens such as BMP-7 and cartilage-derived morphogenetic proteins (CDMPs)], transforming growth factor-&#x003b2; (TGF-&#x003b2;) and &#x0fb01;broblast growth factors (FGFs). CDMP-1 is expressed in the deeper damaged areas of the cartilage of osteoarthritic joints where it leads to an increase of the local chondrocytes but also promotes the local production of proteoglycans[<xref rid="B8" ref-type="bibr">8</xref>,<xref rid="B9" ref-type="bibr">9</xref>].</p><p>Among the morphogens above, BMP-7 leads an important role for the maintenance of the joint homeostasis. Normally, BMP-7 emerges in the upper matrix of articular cartilage adhering to the expression of BMP receptors (BMPR-IA, IB, and II). BMP-7 has many roles in the in&#x0fb02;ammatory disease of the joint, including the preservation of surfaces of the articular cartilage by promoting the expression of the chondrocyte phenotype of dedifferentiated cells, increasing synthesis of tissue inhibitor of metalloproteinase (TIMP). Moreover, leads to the expression of IGFI, and cytoskeletal proteins of the chondrocytes[<xref rid="B10" ref-type="bibr">10</xref>]. It is also known that multipotent mesenchymal stem cells (MSCs) that express BMPs and BMPRs have been isolated from adult human synovial membrane[<xref rid="B11" ref-type="bibr">11</xref>]. So, it is assumed that morphogens from the TGF-&#x003b2; family seem to be involved in the remodeling of the arthritic cartilage. Components of synovial joints, such as the bone marrow, the synovium and the periosteum, contain MSCs that are capable of inducing chondrogenesis. It is suggested that the unregulation and likely the up regulation of the activity of TGF-&#x003b2; and BMP are likely to make MSCs in numerous joint sites to form excessive amounts of tissues of cartilage, bone and fibre, leading to &#x0fb01;brosis and osteophyte formation, characteristics of joint osteoarthritis. So, any imbalance between the factors above is likely to establish the degenerative joint disease (DJD) which with further progression may lead to the need of a total joint replacement[<xref rid="B12" ref-type="bibr">12</xref>]. However, the bone itself has a leading role in the pathogenesis of osteoarthritis. The level of bone remodeling plays a critical role under mechanical loading conditions, as demonstrated by consistent experimental studies. Yet, new clinical biomarkers have being developed to assess the bone phenotype of osteoarthritic patients. This stratification strategy is likely to better identify groups of patients who would benefit from bone-acting drugs to decrease disease progression and improve pain and disability[<xref rid="B13" ref-type="bibr">13</xref>].</p></sec><sec><title>FETUIN-A (AHSG) IN DJD</title><p>As it was stated above, APPs such as C reactive protein is mentioned to be elevated due to arthritis, depending on the severity of the disease[<xref rid="B14" ref-type="bibr">14</xref>]. Fetuin A protein is also mentioned to be influenced by the inflammation as an APP[<xref rid="B15" ref-type="bibr">15</xref>,<xref rid="B16" ref-type="bibr">16</xref>], in addition to other biomarkers which have been recently studied. For example, serum cartilage oligometric matrix protein was also found elevated in cases of knee joint osteoarthritis[<xref rid="B17" ref-type="bibr">17</xref>,<xref rid="B18" ref-type="bibr">18</xref>]. Interestingly, recent research has shown lower serum levels of AHSG in patients with DJD, accompanied with lower BMP levels than the healthy ones[<xref rid="B12" ref-type="bibr">12</xref>].</p><p>Studies have shown that AHSG is a negative acute phase reactant and its level is correlated with CRP circulation in the serum inversely[<xref rid="B19" ref-type="bibr">19</xref>]. Further research has also shown a close association between fetuin A and metabolic syndrome[<xref rid="B20" ref-type="bibr">20</xref>], obesity and dyslipidemia[<xref rid="B21" ref-type="bibr">21</xref>], or even blood pressure regulation[<xref rid="B22" ref-type="bibr">22</xref>]. Additionally, it has been linked closely with type 2 diabetes mellitus and many authors have suggested that it may be an independent risk factor for the expression of the disease. Specifically, patients with high levels of serum AHSG may have increased risk of incident diabetes[<xref rid="B23" ref-type="bibr">23</xref>,<xref rid="B24" ref-type="bibr">24</xref>]. Mixed results have been drawn regarding the role of fetuin A in the cardiovascular disease. However, all studies have shown a positive or negative effect of the circulating levels and the presence of the disease[<xref rid="B19" ref-type="bibr">19</xref>,<xref rid="B25" ref-type="bibr">25</xref>,<xref rid="B26" ref-type="bibr">26</xref>]. With no exaggeration, one can admit that AHSG is indeed a multifunctional protein[<xref rid="B16" ref-type="bibr">16</xref>]!</p><p>AHSG is an antagonist of the TGF-&#x003b2;/BMP, as it is mentioned that it antagonizes the osteogenic as well as the anti-proliferative actions of TGF-&#x003b2; cytokines <italic>in vitro</italic>. More specifically, the 18-19 amino acid region in the AHSG molecule is identical to the TGF-&#x003b2; receptor type II (TBRII) and appears to be the BMP antagonist site. This domain is also designated the TGF-&#x003b2; receptor II homology 1 domain (TRH1), which is essential for the cytokine binding and as a result leads to the non binding with the TBRII[<xref rid="B27" ref-type="bibr">27</xref>]. So, inflammatory diseases characterized by low serum AHSG, such as DJD, leads to an unregulated binding of TGF-&#x003b2; and BMP, having further &#x0fb01;brosis, osteophyte and ectopic bone formation as a result[<xref rid="B28" ref-type="bibr">28</xref>].</p><p>During the progression of the arthritis, a down regulation of the liver production of AHSG leads to it lower serum levels[<xref rid="B12" ref-type="bibr">12</xref>]. Another explanation for that is likely to be the elevated figures of MMPs which are produced by the inflamed tissues, Especially, MMP-1, 3 and 9 are increased in in&#x0fb02;amed joints. However, recent studies suggest that AHSG can be eliminated by MMPs, either systematically or locally in the joint[<xref rid="B29" ref-type="bibr">29</xref>]. As a result, this could lead to increased activity of the BMPs that would also lead to further progression of the arthritis.</p><p>Regarding the prevention of DJD, it is important to state that the therapeutic interventions and goals should take place during the early stages of the arthritis, as chondrocytes are still able to respond to the anabolic factors[<xref rid="B9" ref-type="bibr">9</xref>]. The existence of a therapeutic window should be established regarding the concentration and the exposure of BMP-7. Moreover, in order to maintain the joint homeostasis it is important that other proteins such as AHSG that are down-regulators of the BMPs, should be available in order to enhance the protective role of the cytokines above.</p><p>As for the therapeutic potential of AHSG in the DJD, Rittenberg et al[<xref rid="B30" ref-type="bibr">30</xref>] described in 2005 the regulated release of intrarticular injections on experimental level of BMP7 by co-injection of its regulatory molecules such as AHSG in clinical trials. Moreover, besides to the regulation of BMPs, therapeutic potential of AHSG is also based on its ability to eliminate the inflammation and the local tissue destruction. In 1998, Wang et al[<xref rid="B31" ref-type="bibr">31</xref>] proved through examination of murine cell cultures that AHSG can be used by the local macrophages as an opsonin for macrophage deactivating molecules. Furthermore, Wang et al[<xref rid="B32" ref-type="bibr">32</xref>] in 2010 established the protective role of AHSG in the ischemic cerebral inflammation in animal models of rats, as well as the the suppression of sepsis mediators in late stages of sepsis in the same animal model. Also, TNF increase from lipopolysaccharide stimulated macrophages was inhibited signi&#x0fb01;cantly in an animal model of in&#x0fb02;ammation which was carried out by Wang et al[<xref rid="B33" ref-type="bibr">33</xref>] in 1997. Consequently, the co-administration of AHSG and BMPs is able to set a therapeutic intervention for the degenerative bone disease, taking into account the anti-inflammatory role of the agents above.</p></sec><sec><title>CONCLUSION</title><p>In conclusion, joint arthritis&#x02019; diagnosis and treatment as well as its pathophysiology have been studied during the years. However, further research seems to be essential for more effective prevention. The protein Fetuin A has the potential to be used as a biomarker of the disease, as well as a therapeutic agent for the DJD. As a result, physicians should be aware of the fetuin A as a marker of activity and also to be informed in order to have a correct approach to the patients disease and treatment, but also for additional inflammatory diseases. Besides, additional clinical studies are likely to validate the measurement of BMPs as well as AHSG serum levels as a diagnostic means in the clinical entity of DJD. The identification of AHSG levels in combination with the clinical evaluation of the patients, are not only likely to diagnose the disease in even subclinical stage but also to reduce the need for any further joint salvage procedures, such as total arthroplasty.</p></sec></body><back><fn-group><fn fn-type="COI-statement"><p>Conflict-of-interest statement: There is no conflict of interest associated with any of the senior author or other co-authors contributed their efforts in this manuscript.</p></fn><fn><p>Manuscript source: Invited manuscript</p></fn><fn><p>Specialty type: Orthopedics</p></fn><fn><p>Country of origin: Greece</p></fn><fn><p>Peer-review report classification</p></fn><fn><p>Grade A (Excellent): 0</p></fn><fn><p>Grade B (Very good): B</p></fn><fn><p>Grade C (Good): C, C</p></fn><fn><p>Grade D (Fair): D</p></fn><fn><p>Grade E (Poor): 0</p></fn><fn><p>Peer-review started: January 21, 2017</p></fn><fn><p>First decision: March 8, 2017</p></fn><fn><p>Article in press: May 5, 2017</p></fn><fn><p>P- Reviewer: Garip Y, Saviola G, Song J, Saviola G S- Editor: Song XX L- Editor: A E- Editor: Lu YJ</p></fn></fn-group><ref-list><ref id="B1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goldring</surname><given-names>SR</given-names></name><name><surname>Goldring</surname><given-names>MB</given-names></name></person-group><article-title>Clinical aspects, pathology and pathophysiology of osteoarthritis</article-title><source>J Musculoskelet Neuronal Interact</source><year>2006</year><volume>6</volume><fpage>376</fpage><lpage>378</lpage><pub-id pub-id-type="pmid">17185832</pub-id></element-citation></ref><ref id="B2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hulejov&#x000e1;</surname><given-names>H</given-names></name><name><surname>Baresov&#x000e1;</surname><given-names>V</given-names></name><name><surname>Kl&#x000e9;zl</surname><given-names>Z</given-names></name><name><surname>Polansk&#x000e1;</surname><given-names>M</given-names></name><name><surname>Adam</surname><given-names>M</given-names></name><name><surname>Senolt</surname><given-names>L</given-names></name></person-group><article-title>Increased level of cytokines and matrix metalloproteinases in osteoarthritic subchondral bone</article-title><source>Cytokine</source><year>2007</year><volume>38</volume><fpage>151</fpage><lpage>156</lpage><pub-id pub-id-type="pmid">17689092</pub-id></element-citation></ref><ref id="B3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Attur</surname><given-names>M</given-names></name><name><surname>Krasnokutsky-Samuels</surname><given-names>S</given-names></name><name><surname>Samuels</surname><given-names>J</given-names></name><name><surname>Abramson</surname><given-names>SB</given-names></name></person-group><article-title>Prognostic biomarkers in osteoarthritis</article-title><source>Curr Opin Rheumatol</source><year>2013</year><volume>25</volume><fpage>136</fpage><lpage>144</lpage><pub-id pub-id-type="pmid">23169101</pub-id></element-citation></ref><ref id="B4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xiao</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>XR</given-names></name><name><surname>Hu</surname><given-names>KZ</given-names></name><name><surname>Li</surname><given-names>MQ</given-names></name><name><surname>Chen</surname><given-names>JW</given-names></name><name><surname>Ma</surname><given-names>T</given-names></name><name><surname>Li</surname><given-names>ZC</given-names></name></person-group><article-title>Serum fetuin-A levels are inversely associated with clinical severity in patients with primary knee osteoarthritis</article-title><source>Biomarkers</source><year>2013</year><volume>18</volume><fpage>51</fpage><lpage>54</lpage><pub-id pub-id-type="pmid">23066960</pub-id></element-citation></ref><ref id="B5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baenziger</surname><given-names>JU</given-names></name><name><surname>Fiete</surname><given-names>D</given-names></name></person-group><article-title>Structure of the complex oligosaccharides of fetuin</article-title><source>J Biol Chem</source><year>1979</year><volume>254</volume><fpage>789</fpage><lpage>795</lpage><pub-id pub-id-type="pmid">83994</pub-id></element-citation></ref><ref id="B6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pedersen</surname><given-names>K</given-names></name></person-group><article-title>Fetuin, a new globin isolated from serum</article-title><source>Nature</source><year>1944</year><fpage>575</fpage><lpage>570</lpage></element-citation></ref><ref id="B7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Sama</surname><given-names>AE</given-names></name></person-group><article-title>Anti-inflammatory role of fetuin-A in injury and infection</article-title><source>Curr Mol Med</source><year>2012</year><volume>12</volume><fpage>625</fpage><lpage>633</lpage><pub-id pub-id-type="pmid">22292896</pub-id></element-citation></ref><ref id="B8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Suzuki</surname><given-names>T</given-names></name><name><surname>Bessho</surname><given-names>K</given-names></name><name><surname>Segami</surname><given-names>N</given-names></name><name><surname>Nojima</surname><given-names>T</given-names></name><name><surname>Iizuka</surname><given-names>T</given-names></name></person-group><article-title>Bone morphogenetic protein-2 in temporomandibular joints with internal derangement</article-title><source>Oral Surg Oral Med Oral Pathol Oral Radiol Endod</source><year>1999</year><volume>88</volume><fpage>670</fpage><lpage>673</lpage><pub-id pub-id-type="pmid">10625847</pub-id></element-citation></ref><ref id="B9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goldring</surname><given-names>MB</given-names></name></person-group><article-title>Update on the biology of the chondrocyte and new approaches to treating cartilage diseases</article-title><source>Best Pract Res Clin Rheumatol</source><year>2006</year><volume>20</volume><fpage>1003</fpage><lpage>1025</lpage><pub-id pub-id-type="pmid">16980220</pub-id></element-citation></ref><ref id="B10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chubinskaya</surname><given-names>S</given-names></name><name><surname>Hurtig</surname><given-names>M</given-names></name><name><surname>Rueger</surname><given-names>DC</given-names></name></person-group><article-title>OP-1/BMP-7 in cartilage repair</article-title><source>Int Orthop</source><year>2007</year><volume>31</volume><fpage>773</fpage><lpage>781</lpage><pub-id pub-id-type="pmid">17687553</pub-id></element-citation></ref><ref id="B11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Luyten</surname><given-names>FP</given-names></name></person-group><article-title>Mesenchymal stem cells in osteoarthritis</article-title><source>Curr Opin Rheumatol</source><year>2004</year><volume>16</volume><fpage>599</fpage><lpage>603</lpage><pub-id pub-id-type="pmid">15314501</pub-id></element-citation></ref><ref id="B12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Albilia</surname><given-names>JB</given-names></name><name><surname>Tenenbaum</surname><given-names>HC</given-names></name><name><surname>Clokie</surname><given-names>CM</given-names></name><name><surname>Walt</surname><given-names>DR</given-names></name><name><surname>Baker</surname><given-names>GI</given-names></name><name><surname>Psutka</surname><given-names>DJ</given-names></name><name><surname>Backstein</surname><given-names>D</given-names></name><name><surname>Peel</surname><given-names>SA</given-names></name></person-group><article-title>Serum levels of BMP-2, 4, 7 and AHSG in patients with degenerative joint disease requiring total arthroplasty of the hip and temporomandibular joints</article-title><source>J Orthop Res</source><year>2013</year><volume>31</volume><fpage>44</fpage><lpage>52</lpage><pub-id pub-id-type="pmid">22778059</pub-id></element-citation></ref><ref id="B13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Funck-Brentano</surname><given-names>T</given-names></name><name><surname>Cohen-Solal</surname><given-names>M</given-names></name></person-group><article-title>Subchondral bone and osteoarthritis</article-title><source>Curr Opin Rheumatol</source><year>2015</year><volume>27</volume><fpage>420</fpage><lpage>426</lpage><pub-id pub-id-type="pmid">26002035</pub-id></element-citation></ref><ref id="B14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Przepiera-B&#x00119;dzak</surname><given-names>H</given-names></name><name><surname>Fischer</surname><given-names>K</given-names></name><name><surname>Brzosko</surname><given-names>M</given-names></name></person-group><article-title>Serum Interleukin-18, Fetuin-A, Soluble Intercellular Adhesion Molecule-1, and Endothelin-1 in Ankylosing Spondylitis, Psoriatic Arthritis, and SAPHO Syndrome</article-title><source>Int J Mol Sci</source><year>2016</year><volume>17</volume></element-citation></ref><ref id="B15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dabrowska</surname><given-names>AM</given-names></name><name><surname>Tarach</surname><given-names>JS</given-names></name><name><surname>Wojtysiak-Duma</surname><given-names>B</given-names></name><name><surname>Duma</surname><given-names>D</given-names></name></person-group><article-title>Fetuin-A (AHSG) and its usefulness in clinical practice. Review of the literature</article-title><source>Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub</source><year>2015</year><volume>159</volume><fpage>352</fpage><lpage>359</lpage><pub-id pub-id-type="pmid">25916279</pub-id></element-citation></ref><ref id="B16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mori</surname><given-names>K</given-names></name><name><surname>Emoto</surname><given-names>M</given-names></name><name><surname>Inaba</surname><given-names>M</given-names></name></person-group><article-title>Fetuin-A: a multifunctional protein</article-title><source>Recent Pat Endocr Metab Immune Drug Discov</source><year>2011</year><volume>5</volume><fpage>124</fpage><lpage>146</lpage><pub-id pub-id-type="pmid">22074587</pub-id></element-citation></ref><ref id="B17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Verma</surname><given-names>P</given-names></name><name><surname>Dalal</surname><given-names>K</given-names></name></person-group><article-title>Serum cartilage oligomeric matrix protein (COMP) in knee osteoarthritis: a novel diagnostic and prognostic biomarker</article-title><source>J Orthop Res</source><year>2013</year><volume>31</volume><fpage>999</fpage><lpage>1006</lpage><pub-id pub-id-type="pmid">23423905</pub-id></element-citation></ref><ref id="B18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tseng</surname><given-names>S</given-names></name><name><surname>Reddi</surname><given-names>AH</given-names></name><name><surname>Di Cesare</surname><given-names>PE</given-names></name></person-group><article-title>Cartilage Oligomeric Matrix Protein (COMP): A Biomarker of Arthritis</article-title><source>Biomark Insights</source><year>2009</year><volume>4</volume><fpage>33</fpage><lpage>44</lpage><pub-id pub-id-type="pmid">19652761</pub-id></element-citation></ref><ref id="B19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>V&#x000f6;r&#x000f6;s</surname><given-names>K</given-names></name><name><surname>Gr&#x000e1;f</surname><given-names>L</given-names></name><name><surname>Proh&#x000e1;szka</surname><given-names>Z</given-names></name><name><surname>Gr&#x000e1;f</surname><given-names>L</given-names></name><name><surname>Szenthe</surname><given-names>P</given-names></name><name><surname>Kasz&#x000e1;s</surname><given-names>E</given-names></name><name><surname>B&#x000f6;r&#x000f6;cz</surname><given-names>Z</given-names></name><name><surname>Cseh</surname><given-names>K</given-names></name><name><surname>Kalabay</surname><given-names>L</given-names></name></person-group><article-title>Serum fetuin-A in metabolic and inflammatory pathways in patients with myocardial infarction</article-title><source>Eur J Clin Invest</source><year>2011</year><volume>41</volume><fpage>703</fpage><lpage>709</lpage><pub-id pub-id-type="pmid">21226708</pub-id></element-citation></ref><ref id="B20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ix</surname><given-names>JH</given-names></name><name><surname>Shlipak</surname><given-names>MG</given-names></name><name><surname>Brandenburg</surname><given-names>VM</given-names></name><name><surname>Ali</surname><given-names>S</given-names></name><name><surname>Ketteler</surname><given-names>M</given-names></name><name><surname>Whooley</surname><given-names>MA</given-names></name></person-group><article-title>Association between human fetuin-A and the metabolic syndrome: data from the Heart and Soul Study</article-title><source>Circulation</source><year>2006</year><volume>113</volume><fpage>1760</fpage><lpage>1767</lpage><pub-id pub-id-type="pmid">16567568</pub-id></element-citation></ref><ref id="B21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>HY</given-names></name><name><surname>Chiu</surname><given-names>YL</given-names></name><name><surname>Hsu</surname><given-names>SP</given-names></name><name><surname>Pai</surname><given-names>MF</given-names></name><name><surname>Lai</surname><given-names>CF</given-names></name><name><surname>Peng</surname><given-names>YS</given-names></name><name><surname>Kao</surname><given-names>TW</given-names></name><name><surname>Hung</surname><given-names>KY</given-names></name><name><surname>Tsai</surname><given-names>TJ</given-names></name><name><surname>Wu</surname><given-names>KD</given-names></name></person-group><article-title>Association of serum fetuin A with truncal obesity and dyslipidemia in non-diabetic hemodialysis patients</article-title><source>Eur J Endocrinol</source><year>2009</year><volume>160</volume><fpage>777</fpage><lpage>783</lpage><pub-id pub-id-type="pmid">19228823</pub-id></element-citation></ref><ref id="B22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lavebratt</surname><given-names>C</given-names></name><name><surname>Wahlqvist</surname><given-names>S</given-names></name><name><surname>Nordfors</surname><given-names>L</given-names></name><name><surname>Hoffstedt</surname><given-names>J</given-names></name><name><surname>Arner</surname><given-names>P</given-names></name></person-group><article-title>AHSG gene variant is associated with leanness among Swedish men</article-title><source>Hum Genet</source><year>2005</year><volume>117</volume><fpage>54</fpage><lpage>60</lpage><pub-id pub-id-type="pmid">15806395</pub-id></element-citation></ref><ref id="B23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Laughlin</surname><given-names>GA</given-names></name><name><surname>Barrett-Connor</surname><given-names>E</given-names></name><name><surname>Cummins</surname><given-names>KM</given-names></name><name><surname>Daniels</surname><given-names>LB</given-names></name><name><surname>Wassel</surname><given-names>CL</given-names></name><name><surname>Ix</surname><given-names>JH</given-names></name></person-group><article-title>Sex-specific association of fetuin-A with type 2 diabetes in older community-dwelling adults: the Rancho Bernardo study</article-title><source>Diabetes Care</source><year>2013</year><volume>36</volume><fpage>1994</fpage><lpage>2000</lpage><pub-id pub-id-type="pmid">23315604</pub-id></element-citation></ref><ref id="B24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ix</surname><given-names>JH</given-names></name><name><surname>Wassel</surname><given-names>CL</given-names></name><name><surname>Kanaya</surname><given-names>AM</given-names></name><name><surname>Vittinghoff</surname><given-names>E</given-names></name><name><surname>Johnson</surname><given-names>KC</given-names></name><name><surname>Koster</surname><given-names>A</given-names></name><name><surname>Cauley</surname><given-names>JA</given-names></name><name><surname>Harris</surname><given-names>TB</given-names></name><name><surname>Cummings</surname><given-names>SR</given-names></name><name><surname>Shlipak</surname><given-names>MG</given-names></name></person-group><article-title>Fetuin-A and incident diabetes mellitus in older persons</article-title><source>JAMA</source><year>2008</year><volume>300</volume><fpage>182</fpage><lpage>188</lpage><pub-id pub-id-type="pmid">18612115</pub-id></element-citation></ref><ref id="B25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weikert</surname><given-names>C</given-names></name><name><surname>Stefan</surname><given-names>N</given-names></name><name><surname>Schulze</surname><given-names>MB</given-names></name><name><surname>Pischon</surname><given-names>T</given-names></name><name><surname>Berger</surname><given-names>K</given-names></name><name><surname>Joost</surname><given-names>HG</given-names></name><name><surname>H&#x000e4;ring</surname><given-names>HU</given-names></name><name><surname>Boeing</surname><given-names>H</given-names></name><name><surname>Fritsche</surname><given-names>A</given-names></name></person-group><article-title>Plasma fetuin-a levels and the risk of myocardial infarction and ischemic stroke</article-title><source>Circulation</source><year>2008</year><volume>118</volume><fpage>2555</fpage><lpage>2562</lpage><pub-id pub-id-type="pmid">19029462</pub-id></element-citation></ref><ref id="B26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>ZW</given-names></name><name><surname>Lin</surname><given-names>CG</given-names></name><name><surname>Wu</surname><given-names>LZ</given-names></name><name><surname>Luo</surname><given-names>YK</given-names></name><name><surname>Fan</surname><given-names>L</given-names></name><name><surname>Dong</surname><given-names>XF</given-names></name><name><surname>Zheng</surname><given-names>H</given-names></name></person-group><article-title>Serum fetuin-A levels are associated with the presence and severity of coronary artery disease in patients with type 2 diabetes</article-title><source>Biomarkers</source><year>2013</year><volume>18</volume><fpage>160</fpage><lpage>164</lpage><pub-id pub-id-type="pmid">23410047</pub-id></element-citation></ref><ref id="B27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Demetriou</surname><given-names>M</given-names></name><name><surname>Binkert</surname><given-names>C</given-names></name><name><surname>Sukhu</surname><given-names>B</given-names></name><name><surname>Tenenbaum</surname><given-names>HC</given-names></name><name><surname>Dennis</surname><given-names>JW</given-names></name></person-group><article-title>Fetuin/alpha2-HS glycoprotein is a transforming growth factor-beta type II receptor mimic and cytokine antagonist</article-title><source>J Biol Chem</source><year>1996</year><volume>271</volume><fpage>12755</fpage><lpage>12761</lpage><pub-id pub-id-type="pmid">8662721</pub-id></element-citation></ref><ref id="B28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van der Kraan</surname><given-names>PM</given-names></name><name><surname>van den Berg</surname><given-names>WB</given-names></name></person-group><article-title>Osteophytes: relevance and biology</article-title><source>Osteoarthritis Cartilage</source><year>2007</year><volume>15</volume><fpage>237</fpage><lpage>244</lpage><pub-id pub-id-type="pmid">17204437</pub-id></element-citation></ref><ref id="B29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>So</surname><given-names>A</given-names></name><name><surname>Chamot</surname><given-names>AM</given-names></name><name><surname>P&#x000e9;clat</surname><given-names>V</given-names></name><name><surname>Gerster</surname><given-names>JC</given-names></name></person-group><article-title>Serum MMP-3 in rheumatoid arthritis: correlation with systemic inflammation but not with erosive status</article-title><source>Rheumatology (Oxford)</source><year>1999</year><volume>38</volume><fpage>407</fpage><lpage>410</lpage><pub-id pub-id-type="pmid">10371277</pub-id></element-citation></ref><ref id="B30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rittenberg</surname><given-names>B</given-names></name><name><surname>Partridge</surname><given-names>E</given-names></name><name><surname>Baker</surname><given-names>G</given-names></name><name><surname>Clokie</surname><given-names>C</given-names></name><name><surname>Zohar</surname><given-names>R</given-names></name><name><surname>Dennis</surname><given-names>JW</given-names></name><name><surname>Tenenbaum</surname><given-names>HC</given-names></name></person-group><article-title>Regulation of BMP-induced ectopic bone formation by Ahsg</article-title><source>J Orthop Res</source><year>2005</year><volume>23</volume><fpage>653</fpage><lpage>662</lpage><pub-id pub-id-type="pmid">15885488</pub-id></element-citation></ref><ref id="B31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Zhang</surname><given-names>M</given-names></name><name><surname>Bianchi</surname><given-names>M</given-names></name><name><surname>Sherry</surname><given-names>B</given-names></name><name><surname>Sama</surname><given-names>A</given-names></name><name><surname>Tracey</surname><given-names>KJ</given-names></name></person-group><article-title>Fetuin (alpha2-HS-glycoprotein) opsonizes cationic macrophagedeactivating molecules</article-title><source>Proc Natl Acad Sci USA</source><year>1998</year><volume>95</volume><fpage>14429</fpage><lpage>14434</lpage><pub-id pub-id-type="pmid">9826717</pub-id></element-citation></ref><ref id="B32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Li</surname><given-names>W</given-names></name><name><surname>Zhu</surname><given-names>S</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Ward</surname><given-names>MF</given-names></name><name><surname>Huang</surname><given-names>Y</given-names></name><name><surname>Yang</surname><given-names>H</given-names></name><name><surname>Tracey</surname><given-names>KJ</given-names></name><name><surname>Wang</surname><given-names>P</given-names></name><name><surname>Sama</surname><given-names>AE</given-names></name></person-group><article-title>Fetuin protects mice against lethal sepsis by modulating bacterial endotoxin induced hmgb1 release and autophagy</article-title><source>Shock</source><year>2010</year><volume>33</volume><issue>Suppl 1</issue><fpage>1</fpage><lpage>13</lpage><pub-id pub-id-type="pmid">19996915</pub-id></element-citation></ref><ref id="B33"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Zhang</surname><given-names>M</given-names></name><name><surname>Soda</surname><given-names>K</given-names></name><name><surname>Sama</surname><given-names>A</given-names></name><name><surname>Tracey</surname><given-names>KJ</given-names></name></person-group><article-title>Fetuin protects the fetus from TNF</article-title><source>Lancet</source><year>1997</year><volume>350</volume><fpage>861</fpage><lpage>862</lpage></element-citation></ref></ref-list></back></article>